Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Acquisitions & Divestments (2017 - 2025)

Protagonist Therapeutics' Change in Acquisitions & Divestments history spans 9 years, with the latest figure at -$331.6 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 412.85% year-over-year to -$331.6 million; the TTM value through Dec 2025 reached $7.0 million, down 97.84%, while the annual FY2025 figure was $7.0 million, 97.84% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was -$331.6 million at Protagonist Therapeutics, down from $102.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $229.0 million in Q2 2025 and bottomed at -$331.6 million in Q4 2025.
  • The 5-year median for Change in Acquisitions & Divestments is $65.4 million (2021), against an average of $53.1 million.
  • The largest annual shift saw Change in Acquisitions & Divestments soared 188.81% in 2024 before it plummeted 412.85% in 2025.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $58.8 million in 2021, then soared by 44.0% to $84.6 million in 2022, then plummeted by 56.62% to $36.7 million in 2023, then skyrocketed by 188.81% to $106.0 million in 2024, then tumbled by 412.85% to -$331.6 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Change in Acquisitions & Divestments are -$331.6 million (Q4 2025), $102.6 million (Q3 2025), and $229.0 million (Q2 2025).